Literature DB >> 9443042

Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation.

D J Marsh1, P L Dahia, V Coulon, Z Zheng, F Dorion-Bonnet, K M Call, R Little, A Y Lin, R A Eeles, A M Goldstein, S V Hodgson, A L Richardson, B G Robinson, H C Weber, M Longy, C Eng.   

Abstract

Cowden disease (CD) is a rare, autosomal dominant inherited cancer syndrome characterized by multiple benign and malignant lesions in a wide spectrum of tissues. While individuals with CD have an increased risk of breast and thyroid neoplasms, the primary features of CD are hamartomas. The gene for CD has been mapped by linkage analysis to a 6 cM region on the long arm of chromosome 10 at 10q22-23. Loss of heterozygosity (LOH) studies of sporadic follicular thyroid adenomas and carcinomas, both component tumors of CD, have suggested that the putative susceptibility gene for CD is a tumor suppressor gene. Somatic missense and nonsense mutations have recently been identified in breast, prostate, and brain tumor cell lines in a gene encoding a dual specificity phosphatase, PTEN/MMACI, mapped at 10q23.3. Furthermore, germline PTEN/MMACI mutations are associated with CD. In the present study, 20 hamartomas from 11 individuals belonging to ten unrelated families with CD have been examined for LOH of markers flanking and within PTEN/MMACI. Eight of these ten families have germline PTEN/MMACI mutations. LOH involving microsatellite markers within the CD interval, and including PTEN/MMACI, was identified in two fibroadenomas of the breast, a thyroid adenoma, and a pulmonary hamartoma belonging to 3 to 11 (27%) of these patients. The wild-type allele was lost in these hamartomas. Semi-quantitative PCR performed on RNA from hamartomas from three different tissues from a CD patient suggested substantial reduction of PTEN/MMACI RNA levels in all of these tissues. The LOH identified in samples from individuals with CD and the suggestion of allelic loss and reduced transcription in hamartomas from a CD patient provide evidence that PTEN/MMACI functions as a tumor suppressor in CD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9443042     DOI: 10.1002/(sici)1098-2264(199801)21:1<61::aid-gcc8>3.0.co;2-6

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  23 in total

1.  Landscaper seeks remunerative position.

Authors:  R J Playford
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

2.  Phosphorylation of the PTEN tail regulates protein stability and function.

Authors:  F Vazquez; S Ramaswamy; N Nakamura; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

3.  Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway.

Authors:  S Ramaswamy; N Nakamura; F Vazquez; D B Batt; S Perera; T M Roberts; W R Sellers
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 4.  Molecular pathology of thyroid cancer: diagnostic and clinical implications.

Authors:  James A Fagin; Nicholas Mitsiades
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2008-12       Impact factor: 4.690

Review 5.  PTEN function: the long and the short of it.

Authors:  Benjamin D Hopkins; Cindy Hodakoski; Douglas Barrows; Sarah M Mense; Ramon E Parsons
Journal:  Trends Biochem Sci       Date:  2014-03-18       Impact factor: 13.807

6.  Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes.

Authors:  Capucine Delnatte; Damien Sanlaville; Jean-Francois Mougenot; Joris-Robert Vermeesch; Claude Houdayer; Marie-Christine de Blois; David Genevieve; Olivier Goulet; Jean-Pierre Fryns; Francis Jaubert; Michel Vekemans; Stanislas Lyonnet; Serge Romana; Charis Eng; Dominique Stoppa-Lyonnet
Journal:  Am J Hum Genet       Date:  2006-04-14       Impact factor: 11.025

7.  Male breast cancer in Cowden syndrome patients with germline PTEN mutations.

Authors:  J D Fackenthal; D J Marsh; A L Richardson; S A Cummings; C Eng; B G Robinson; O I Olopade
Journal:  J Med Genet       Date:  2001-03       Impact factor: 6.318

8.  Pancreatic adenocarcinoma with a germline PTEN p.Arg234Gln mutation.

Authors:  Sunao Uemura; Hiroyuki Matsubayashi; Yoshimi Kiyozumi; Katsuhiko Uesaka; Yusuke Yamamoto; Keiko Sasaki; Masato Abe; Kenichi Urakami; Masatoshi Kusuhara; Ken Yamaguchi
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

9.  Where Birt-Hogg-Dubé meets Cowden syndrome: mirrored genetic defects in two cases of syndromic oncocytic tumours.

Authors:  Laura Maria Pradella; Martin Lang; Ivana Kurelac; Elisa Mariani; Flora Guerra; Roberta Zuntini; Giovanni Tallini; Alan MacKay; Jorge S Reis-Filho; Marco Seri; Daniela Turchetti; Giuseppe Gasparre
Journal:  Eur J Hum Genet       Date:  2013-02-06       Impact factor: 4.246

10.  Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer and Cowden-like phenotypes.

Authors:  Joanne Ngeow; Xin He; Jessica L Mester; Junying Lei; Todd Romigh; Mohammed S Orloff; Mira Milas; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.